Takeda’s Pevonedistat Fails to Meet Primary Endpoints in P-III PANTHER Trial as 1L Treatment for Patients with Rare Bone Marrow Cancer

September 2, 2021 Auto Bot cancer, Clinical Trials, P-III, Takeda 0

Shots:

  • The P-III PANTHER trial evaluates pevonedistat + azacitidine vs azacitidine alone in patients with higher-risk MDS, CMML and AML
  • The study did not achieve its pre-defined 1EPs of EFS, the safety profile was consistent with previously reported data of the combination regimen
  • Pevonedistat is an NAE inhibitor that leads to cancer cell death by disrupting protein homeostasis. Additionally, the results will be submitted for presentation at an upcoming medical congress

Click here to­ read full press release/ article | Ref: Takeda | Image: Pharmaceutical Technology

The post Takeda’s Pevonedistat Fails to Meet Primary Endpoints in P-III PANTHER Trial as 1L Treatment for Patients with Rare Bone Marrow Cancer first appeared on PharmaShots.